These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 25149466

  • 1. Complement component C5a permits the coexistence of pathogenic Th17 cells and type I IFN in lupus.
    Pawaria S, Ramani K, Maers K, Liu Y, Kane LP, Levesque MC, Biswas PS.
    J Immunol; 2014 Oct 01; 193(7):3288-95. PubMed ID: 25149466
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in Trypanosoma cruzi infection.
    Schmitz V, Almeida LN, Svensjö E, Monteiro AC, Köhl J, Scharfstein J.
    J Immunol; 2014 Oct 01; 193(7):3613-23. PubMed ID: 25187655
    [Abstract] [Full Text] [Related]

  • 5. C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression.
    Xu GL, Chen J, Yang F, Li GQ, Zheng LX, Wu YZ.
    Hepatology; 2014 Jul 01; 60(1):114-24. PubMed ID: 24604562
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation.
    Tang M, Zhang K, Li Y, He QH, Li GQ, Zheng QY, Zhang KQ.
    Int Urol Nephrol; 2018 Aug 01; 50(8):1545-1553. PubMed ID: 29594894
    [Abstract] [Full Text] [Related]

  • 11. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice.
    Moulton RA, Mashruwala MA, Smith AK, Lindsey DR, Wetsel RA, Haviland DL, Hunter RL, Jagannath C.
    J Leukoc Biol; 2007 Oct 01; 82(4):956-67. PubMed ID: 17675563
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages.
    Bosmann M, Haggadone MD, Hemmila MR, Zetoune FS, Sarma JV, Ward PA.
    J Immunol; 2012 May 15; 188(10):5086-93. PubMed ID: 22491257
    [Abstract] [Full Text] [Related]

  • 14. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component.
    Zhang W, Xu W, Xiong S.
    J Immunol; 2011 Aug 15; 187(4):1764-77. PubMed ID: 21753147
    [Abstract] [Full Text] [Related]

  • 15. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice.
    Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC.
    J Am Soc Nephrol; 2005 Dec 15; 16(12):3572-82. PubMed ID: 16207826
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. IL-17: a new actor in IFN-driven systemic autoimmune diseases.
    Ambrosi A, Espinosa A, Wahren-Herlenius M.
    Eur J Immunol; 2012 Sep 15; 42(9):2274-84. PubMed ID: 22949326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.